Core Viewpoint - As of February 6, 2026, Meihao Medical (301363) closed at 30.72 yuan, down 2.13%, with a turnover rate of 2.19% and a trading volume of 81,800 hands, amounting to a transaction value of 253 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year; however, the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [3] - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit attributable to shareholders of 93.9 million yuan, an increase of 5.89% year-on-year [3] - The company's gross profit margin stands at 39.34%, with a debt ratio of 11.43% and investment income of 4.9031 million yuan [3] Group 2: Capital Flow - On February 6, 2026, the net outflow of main funds was 30.2992 million yuan, accounting for 12.0% of the total transaction value, while retail investors saw a net inflow of 44.8052 million yuan, representing 17.74% of the total transaction value [1] - The financing data indicates that on the same day, the financing buy amounted to 19.314 million yuan, while financing repayment was 27.6883 million yuan, resulting in a net repayment of 8.3743 million yuan [2] - The total financing and securities balance is 287 million yuan, with a securities balance of 1.136 million yuan [2] Group 3: Market Sentiment - In the last 90 days, seven institutions have given buy ratings for Meihao Medical, with an average target price of 24.57 yuan [4]
美好医疗（301363）2月6日主力资金净卖出3029.92万元